Stay updated with breaking news from Nasdaq Tech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bio-Techne (NASDAQ:TECH – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Friday, Zacks.com reports. The firm currently has a $408.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective would indicate a potential upside of 14.79% from […]
Bio-Techne Co. (NASDAQ:TECH – Get Rating) CEO Charles R. Kummeth sold 5,104 shares of the company’s stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $365.00, for a total transaction of $1,862,960.00. Following the transaction, the chief executive officer now directly owns 198,338 shares in the company, […]
Shares of Bio-Techne Co. (NASDAQ:TECH – Get Rating) have been assigned an average recommendation of “Buy” from the eight ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. […]
Bio-Techne (NASDAQ:TECH – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It […]
Several analysts have recently updated their ratings and price targets for Bio-Techne (NASDAQ: TECH): 5/12/2022 – Bio-Techne was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $394.00 price target on the stock. According to Zacks, “Bio-Techne Corporation is a global life sciences company. It […]